Dr. Luke on the Combination of Pembrolizumab and T-VEC for Melanoma
Jason Luke, MD
Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the combination of pembrolizumab (Keytruda) and talimogene laherparepvec (T-VEC; Imlygic) for the treatment of patients with melanoma.
A combination that is of a lot of interest is a PD-1 antibody and an oncolytic virus, states Luke. There are drugs that are approved for each as a monotherapy, but the combination of pembrolizumab and T-VEC has the potential to be promising.
T-VEC is a modified virus that is injected into melanoma tumors that are on the skin.